Introduction
============

According to a large-scale survey of 36 types of cancer spanning 185 countries in 2018, lung cancer ranks first in the global cancer incidence (11.6%) and mortality rates (18.4%) ([@b1-ol-0-0-10977]). In China, lung cancer also accounts for the highest cancer-related morbidity and mortality ([@b2-ol-0-0-10977]). Among all pathological types of lung cancer, non-small cell lung cancer (NSCLC) accounts for \~80% of cases, making it the most common histological type, with a 5-year survival rate of only 15%. Patients with lung cancer are usually diagnosed at an advanced stage ([@b3-ol-0-0-10977]). However, with the widespread application of low-dose helical computed tomography (CT) in clinical practice, early- or intermediate-stage NSCLC is being diagnosed in an increasing number of asymptomatic patients ([@b4-ol-0-0-10977]). For patients with early- or intermediate-stage lung cancer, surgery is the first and most effective treatment method, as well as the only method that can cure NSCLC. However, the influence of different surgical methods on the prognosis of patients is still controversial ([@b5-ol-0-0-10977]--[@b7-ol-0-0-10977]).

The concept of precision medicine ([@b8-ol-0-0-10977]) has facilitated the development of medical methodology specific to the patient. In contrast to the original 'one size fits all' approach, medical professionals can adjust the treatment according to subtle differences in patients to maximize the outcome. Based on this, the latest (8th) edition of the Tumor-Node-Metastasis (TNM) staging system can more accurately predict the prognosis of lung cancer patients ([@b9-ol-0-0-10977]). However, it is necessary to combine variables such as age, sex, degree of tumor differentiation and treatment to further predict the survival rate of patients with lung cancer, as predicting the prognosis of patients exclusively by TNM stage of NSCLC is insufficient.

Nomograms are based on multifactor regression analyses and integrate multiple predictive indexes with visual graphics, which makes the results of the prediction model readable and the prognosis of patients easy to evaluate ([@b10-ol-0-0-10977]). Despite a number of nomograms based on large samples for predicting the prognosis of patients with lung cancer, limited studies have been performed on stage II or III NSCLC. Therefore, the present study aimed to construct a nomogram based on early ([@b11-ol-0-0-10977],[@b12-ol-0-0-10977]) and advanced ([@b13-ol-0-0-10977]) lung cancer using large-scale data obtained from the Surveillance, Epidemiology and End Results (SEER) database containing information on the clinical characteristics and patient survival.

Materials and methods
=====================

### Data collection

Data were extracted from the SEER database (<https://seer.cancer.gov>) by SEER\*Stat Software (version 8.3.5; <http://seer.cancer.gov/data-software/>), and the Incidence SEER 18 Regs Custom Data (with additional treatment fields), Nov 2017 Sub (1973--2015 varying), were selected for analysis. Data were limited to patients diagnosed with stage II and III lung cancer between January 1, 2010 to November 31, 2015. The retrieval formula based on the inclusion criteria displayed in the software was {Site and Morphology. CS Schema v0204+}='Lung' AND {Stage-American Joint Committee on Cancer (AJCC). Derived AJCC Stage Group, 7th ed. (2010+)} ='II','IIA','IIA1','IIA2','IIB','IIC','III','IIIA','IIIB','IIIC','IIIC1','IIIC2' AND {Race, Sex, Year Dx, Registry, County, Year of diagnosis}='2010','2011','2012','2013','2014','2015'. The clinical information of the patients included patient ID, age at diagnosis, diagnostic confirmation, race (Caucasian, African-American or other), sex, marital status at diagnosis, histologic type, grade, primary site and laterality, AJCC stage, T stage, N stage, surgery at primary site, scope of regional lymph node surgery, radiation therapy, chemotherapy, survival months, vital status, first malignant primary indicator and sequence number.

Once the preliminary data were obtained, patients were excluded based on the following exclusion criteria: i) Clinical information of the patient was missing; ii) diagnostic confirmation was not consistent with positive histology, such as only clinical diagnosis or direct visualization without microscopic confirmation; iii) patient was \<18 years; iv) survival time was \<1 month; v) the meaning of the patient\'s relevant code was unclear or had other meaning that could not be included in the study; for example, in a surgical procedure, 00 refers to no surgery, 21 refers to wedge resection, 22 refers to segmental resection, and 31 refers to lobectomy, and patients with additional codes, such as 41--49, were excluded; vi) the data point applied to a small number of patients; for example, only 23 patients underwent pneumonectomy and were thus excluded; vii) the patient had more than one primary tumor.

The data were divided into two groups based on patient age (≤60 and \>60 years). In addition, regarding marital status, patients who were widowed, divorced, unmarried or domestic partners and single (unmarried) were all considered unmarried. In terms of pathological types, only four pathological tissue types were included: Adenocarcinoma (ADC), squamous cell carcinoma (SCC), large cell carcinoma (LCC) and adenosquamous carcinoma (ASC). Regarding radiotherapy, patients were divided into two groups: Yes and no, where beam radiation, radioactive implants, and radioisotopes were all considered as 'yes'. The remaining clinical information was determined via the specific meaning of the code and the specific output of the software.

### Statistical analysis

The random allocation method was used to divide the data into a training set and a validation set at a 7:3 ratio. Median survival time with 95% confidence intervals (CIs) for the two groups was determined using the Kaplan-Meier method. In the training cohort, unadjusted univariate Cox regression analysis was used for all variables included in the study. P\<0.05 was considered to indicate a statistically significant difference. Factors with statistical significance according to the results of the unadjusted univariate Cox regression analysis were included in the multivariate Cox regression analysis to identify independent risk factors. These independent risk factors were used to construct a nomogram using R software version 3.5.1 (64 bit; <http://www.r-project.org>) using the rms ([@b14-ol-0-0-10977]) and survival packages (<https://www.rdocumentation.org/packages/survival/versions/2.42-3>). The nomogram used 3- and 5-year overall survival (OS) as end points. Harrell\'s concordance indexes (C-indexes) ([@b15-ol-0-0-10977]) and calibration curves were used to verify the predicted effect of the nomogram. The training set was used for internal validation, and the validation set was used for external validation. Bootstraps of 1,000 resamples were used for analysis. In addition, to validate the ability of the nomogram to discriminate patients with different TNM stages, patients in the validation set were assigned into four groups according to the quartiles of their prognostic scores. The Kaplan-Meier method was used to estimate overall survival rate in the four groups, and the differences were evaluated using the log-rank test with a threshold of P\<0.05.

Results
=======

### Patient clinicopathological characteristics

According to the inclusion and exclusion criteria, 15,344 patients with stage II and III NSCLC were included in the study. Among them, 3,261 patients had stage IIA, 2,865 had stage IIB, 6,851 had stage IIIA and 2,367 had stage IIIB NSCLC. The mean age was 68.41 (range, 15--101 years) years. The patients were divided into two random groups at a ratio of 7:3 to form the training and validation sets, comprising 10,744 and 4,600 patients, respectively. The median survival was 22.00 months and the 3- and 5-year survival rates were 0.638 and 0.512 for the training set. The median survival was 23.50 months and the 3- and 5-year survival rates were 0.666 and 0.551 for the validation set. The clinical characteristics and survival information of the two sets are presented in [Tables I](#tI-ol-0-0-10977){ref-type="table"} and [II](#tII-ol-0-0-10977){ref-type="table"}.

### Cox regression analysis

The following factors were included in the univariate Cox regression analysis: Age (≤60 vs. \>60), race (Caucasian vs. African-American vs. other), sex (male vs. female), marital status (married vs. unmarried), histological type (ADC vs. SCC vs. LCC vs. ADC), grade (well differentiated, grade I vs. moderately differentiated, grade II vs. poorly differentiated, grade III vs. undifferentiated or anaplastic, grade IV), primary site (main bronchus vs. upper lobe vs. middle lobe vs. lower lobe), latency (left vs. right), T stage (T1 vs. T2 vs. T3 vs. T4), N stage (N0 vs. N1 vs. N2 vs. N3), surgery at primary site (none vs. wedge resection vs. segmental resection vs. lobectomy), scope of regional lymph node surgery (none vs. 1--3 regional lymph nodes removed vs. ≥4 regional lymph nodes removed), radiation therapy (yes vs. no) and chemotherapy (yes vs. no). The results of the univariate Cox regression analysis indicated no significant difference regarding laterality (P=0.353). The remaining prognostic factors with P\<0.05 were included in the multivariate Cox regression analysis. The results demonstrated that all included factors, with the exception of the primary site, were independent prognostic factors and were thus included in the construction of the nomogram ([Table III](#tIII-ol-0-0-10977){ref-type="table"}).

### Construction and validation of the nomogram

The nomogram comprised 12 prognostic factors: Age, sex, race, marital status, histological type, grade, T stage, N stage, surgery type, extent of lymph node dissection, radiation therapy and chemotherapy. Surgery, especially lobectomy, exhibited the strongest impact on prognosis among all factors; chemotherapy also served an important role ([Fig. 1](#f1-ol-0-0-10977){ref-type="fig"}). Marriage had a relatively small effect on prognosis. The effects of other factors on prognosis were moderate. A total score was calculated by adding up the scores of each factor according to the different characteristics. The 3- and 5-year survival rates were estimated by drawing a straight line from the total score on the nomogram. The C-index calculated by the bootstrap self-sampling method was 0.719 (95% CI, 0.718--0.719) in the training set and 0.721 (95% CI, 0.720--0.722) in the validation set, indicating good predictability of the nomogram. In addition, the calibration curve was similar to the standard curve in predicting the 3- and 5-year survival rates of patients from the training set and validation set, indicating good predictive ability of the nomogram ([Figs. 2](#f2-ol-0-0-10977){ref-type="fig"} and [3](#f3-ol-0-0-10977){ref-type="fig"}).

### Risk stratification

The total score for each patient in the training set was calculated, and the scores divided into quartiles (0--137, 138--213, 214--269 and 270--436) to represent different outcomes. A statistically significant difference in survival was identified among patients with stage IIA, IIB, IIIA and IIIB NSCLC when the quartiles of scores were applied to divide the patients in the validation set (all P\<0.001; [Fig. 4](#f4-ol-0-0-10977){ref-type="fig"}).

Discussion
==========

To the best of our knowledge, this is the first large-scale clinical retrospective study that used the SEER database to construct a nomogram to predict survival rates for patients with stage II and III NSCLC. In this study, a total of 15,344 patients were included following rigorous screening, and 12 risk factors that significantly affected prognosis were determined by the Cox regression method. A nomogram was constructed based on these 12 risk factors. The C-index and the graphical calibration method were used for internal validation, which suggested that the nomogram exhibited a good predictive ability. The nomogram demonstrated that the survival of patients with NSCLC was affected by multiple factors, especially the treatment strategy. The nomogram also accurately predicted the prognosis of different risk groups, including patients with stage IIA, IIB, IIIA and IIIB NSCLC. Compared with traditional TNM staging, the model established in the present study combined more clinical information to determine the prognosis of patients more accurately and guide the treatment strategy.

Demographic factors of the patients in the present study, such as age, sex and race, had a moderate influence on prognosis, and marital status only had a minor effect. In elderly patients with NSCLC, the aging of organs coupled with a decrease in immune function leads to a high possibility of tumor recurrence. Elderly patients with NSCLC exhibit low tolerance to surgery, radiotherapy and chemotherapy, and therefore, their compliance to anticancer treatment may be poor. Additionally, elderly patients may often suffer from other conditions, and thus their survival rate is reduced ([@b16-ol-0-0-10977]). Through follow-up of 14,578 postoperative patients with NSCLC between January 2009 and January 2014 in multiple centers, Dziedzic *et al* ([@b17-ol-0-0-10977]) demonstrated that the risk of tumor recurrence and metastasis increased with age. In a retrospective study involving 33,919 patients with lung cancer from Taiwan, China, Wang *et al* ([@b18-ol-0-0-10977]) reported that age \>65 years was an independent risk factor for prognosis. Thus, age is associated with the prognosis of patients with lung cancer.

A recent large-scale epidemiological survey revealed that the incidence and mortality rates of female patients with lung cancer are increasing ([@b1-ol-0-0-10977]). Chang *et al* ([@b19-ol-0-0-10977]) retrospectively analyzed 2,770 patients with stage I and II NSCLC and demonstrated that the 5-year survival rate of female patients with lung ADC was higher compared with that of male patients, whereas no significant differences were observed in the 5-year survival rate of patients with non-adenocarcinoma. However, another study has reported the opposite result, i.e. that sex is not a risk factor for patients with NSCLC ([@b17-ol-0-0-10977]). Although the mechanism by which sex affects the prognosis of patients with lung cancer requires further study, male and female patients exhibit distinctive clinical and biological characteristics, such as the likelihood of ADC. In addition, mutations in the epidermal growth factor receptor gene are often identified in female patients ([@b17-ol-0-0-10977]). Results for non-smoking patients with lung ADC also indicated that female patients may more likely benefit from targeted therapy compared with male patients ([@b20-ol-0-0-10977]).

In terms of marital status, Merrill *et al* ([@b21-ol-0-0-10977]) used a sample of 779,978 male and 1,032,868 female patients from the SEER database and reached the opposite conclusion from that of the present study; marriage was beneficial for only non-fatal cancers such as breast, colorectal and kidney cancer, but did not improve the 5-year survival rate for patients with lung or liver cancer. However, another study that used the SEER database reported that among patients with NSCLC, married individuals exhibited higher overall and tumor-specific survival rates compared with unmarried individuals ([@b22-ol-0-0-10977]). A multicenter trial ([@b23-ol-0-0-10977]) has demonstrated that married patients with cancer experience less psychological distress and receive better social support compared with unmarried patients, which may explain why marriage improved the prognosis of patients with lung cancer. Race is also strongly associated with the prognosis of lung cancer, although this association remains controversial. An epidemiological survey of 38 states in the United States that included 80% of the population revealed that African-American patients exhibited lower survival rates compared with Caucasian patients ([@b24-ol-0-0-10977]). Another retrospective analysis, spanning 10 years in the United States, suggested that racial differences in lung cancer mortality were due to differences in access to health care and provision of the recommended treatment ([@b25-ol-0-0-10977]). In a retrospective study from Florida, the authors noted that Asian patients had higher survival rates compared with Caucasian and African-American patients following adjustment for certain confounding factors, such as economic status ([@b26-ol-0-0-10977]). In addition, the results of the present study suggested that other populations, including Asians, exhibited the best prognosis.

In the present study, the results of the traditional TNM staging of lung cancer were the same as those of NSCLC. Prognosis became progressively worse with increasing T/N stages, and the histopathological type and degree of tumor differentiation also determined the prognosis of patients with lung cancer. Regarding differentiation, poorly differentiated tumors have a stronger ability to invade and metastasize and are highly malignant; the results of the present study also demonstrated that a low degree of tumor differentiation in patients with NSCLC was associated with a low survival rate. There are different views regarding the ability of TNM stage to reflect accurately the prognosis of patients. For example, three retrospective studies from Asia and Europe suggested that patients with different AJCC stages had no statistical difference in prognosis, therefore it was not advisable to rely solely on AJCC stages to determine prognosis, as there are numerous remaining factors affecting the survival of patients with NSCLC ([@b27-ol-0-0-10977]--[@b29-ol-0-0-10977]). A previous study confirmed that gene mutation is one of the possible reasons for the difference in prognosis between lung SCC and ADC ([@b30-ol-0-0-10977]). However, in further studies on NSCLC, more attention should be paid to the pathological types and differentiation degree. For example, the AJCC has advocated that researchers focus on the influence of different pathological types on prognosis in esophageal cancer ([@b31-ol-0-0-10977]).

For patients with NSCLC, appropriate treatment such as surgery or drug therapy should be selected based on the clinical situation of the patients, in order to obtain the optimal prognosis.. In theory, cancer can be cured if drugs that completely eradicate cancer cells were discovered; currently, the ability of drugs to cure cancer is limited to several types of malignant tumors. For the majority of malignant tumors, finding a cure is more likely in the early stages of disease, when the tumor has not spread and can be surgically removed. The present study demonstrated that patients with \>4 groups lymph node metastasis, lobectomy in combination with lymph node dissection was associated with the best prognosis. Speicher *et al* ([@b32-ol-0-0-10977]) have reported that surgical lobectomy significantly prolonged long-term survival in a follow-up study of 39,403 patients with lung cancer. A meta-analysis by Zhang *et al* ([@b33-ol-0-0-10977]) also revealed that lobectomy resulted in better prognosis compared with segmental lung resection in patients with stage I NSCLC, and that age and tumor size should not be considered limiting factors for lobectomy. In addition, the latest National Comprehensive Cancer Network guidelines recommend lobectomy as the first-choice treatment for patients with stage II and III NSCLC with good lung reserve function that can tolerate surgery ([@b34-ol-0-0-10977]). For NSCLC, lymph node metastasis, especially mediastinal lymph node metastasis, is an independent risk factor for poor prognosis ([@b35-ol-0-0-10977]). Lymph node dissection has also been demonstrated to significantly improve prognosis ([@b36-ol-0-0-10977]). In 1996, the International Association for the Study of Lung Cancer presented the concept of systematic lymph node dissection (SLD), with lobectomy combined with SLD identified as the standard surgical method for NSCLC ([@b37-ol-0-0-10977]). In 2006, the guidelines of the European Society of Thoracic Surgeons defined the scope of SLD as the resection of at least six groups of lymph nodes, including \>3 ipsilateral mediastinal and subcarinal lymph nodes. The complete dissection of mediastinal lymph nodes and surrounding adipose tissue is required ([@b38-ol-0-0-10977]). According to the standards of the Japan Lung Cancer Society, Adachi *et al* ([@b39-ol-0-0-10977]) defined lymph node dissection as: i) The removal of at ≥3 hilar and intrapulmonary lymph nodes; ii) the resection of ≥3 mediastinal lymph nodes; or iii) the removal of ≥6 lymph nodes. Similarly, the results of the present study demonstrated that the dissection of ≥4 groups of lymph nodes significantly improved patient survival.

With the emergence of targeted therapy and immunotherapy, the survival advantage of patients receiving conventional platinum-based adjuvant chemotherapy as the standard treatment is moderate, especially for patients with stage II or III NSCLC ([@b40-ol-0-0-10977]). However, a large retrospective study has also reported that postoperative adjuvant chemotherapy is essential for improving the prognosis of patients ([@b41-ol-0-0-10977]). Radiotherapy is also a standard treatment for NSCLC. A large-scale retrospective analysis using the SEER database concluded that preoperative radiotherapy can significantly improve the survival rate of patients with IIIA/N2 NSCLC ([@b42-ol-0-0-10977]). However, radiotherapy results in numerous side effects, such as skin ulcers or severe reactions including radiological pneumonia ([@b43-ol-0-0-10977]). Increasing the dose of radiation appears to improve the prognosis of patients who only receive radiation therapy, but decrease survival in patients who receive a combination of radiotherapy and chemotherapy ([@b44-ol-0-0-10977]). Therefore, the selection of anticancer treatment strategy for patients should be combined with their clinicopathological data.

The present study had several limitations. First, due to the limited information available in the SEER database, smoking history, radiotherapy dose, specific chemotherapy regimen, surgical methods (open or endoscopic surgery) and additional clinical information could not be obtained, which may have affected the results. Second, the T/N staging was based on the 7th edition of the AJCC staging system. Although the 7th edition TN stage and tumor size were available, the tumor invasion degree information was not included, and thus the AJCC staging results could not be converted to the 8th edition. For example, a 600 mm T3 lung cancer record from the SEER database should be classified as T4 according to the 8th edition of AJCC staging if it extends to the diaphragm. Finally, the patients with NSCLC in the SEER database were all from the United States, and although patients of different races were included, the cohort may not be representative of patients worldwide.

In conclusion, a nomogram combining substantial demographic, pathological and treatment data to predict OS for patients with stage II and III NSCLC was established and validated using a population-based study from the SEER database. Well-designed trials are needed to improve this nomogram.
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###### 

Clinical characteristics of the training set.

                                    OS, months   OS, %                                
  ------------------------- ------- ------------ -------------- ---------- ---------- ---------
  Age                                                                                 
    ≤60                     2,360   34           30.61--37.39   48.5±1.2   39.4±1.4   \<0.001
    \>60                    8,384   21           21.13--21.87   35.8±0.6   25.4±0.7   
  Sex                                                                                 
    Male                    5,929   19           18.06--19.94   34.1±0.7   25.9±0.8   \<0.001
    Female                  4,815   29           27.22--30.78   43.3±0.9   31.7±1.0   
  Marital status                                                                      
    Married                 5,896   25           23.67--26.33   34.1±0.7   25.3±0.9   \<0.001
    Unmarried               4,848   21           19.83--22.16   36.1±0.8   25.0±1.0   
  Race                                                                                
    Caucasian               8,623   25           23.67--26.33   37.7±0.6   28.2±0.7   \<0.001
    African-American        1,274   21           19.83--22.17   39.7±1.6   27.1±2.0   
    Other                   847     23           22.15--23.87   46.2±2.1   34.3±2.4   
  Histology                                                                           
    ADC                     5,552   32           30.17--33.83   46.1±0.8   33.9±1.0   \<0.001
    SCC                     4,784   16           15.12--16.87   29.6±0.8   22.2±0.9   
    LCC                     270     22           17.86--26.14   37.0±3.5   26.8±4.2   
    ASC                     138     17           13.13--20.87   78.4±3.6   61.2±4.3   
  Grade                                                                               
    I                       765     31           26.10--35.89   46.4±2.2   30.2±2.9   \<0.001
    II                      4,379   26           24.43--27.56   41.6±0.9   31.1±1.0   
    III                     5,441   20           18.96--21.04   35.3±0.8   26.2±0.9   
    IV                      159     17           12.84--21.16   34.7±4.3   29.8±4.6   
  AJCC (7th) T stage (45)                                                             
    T1                      1,324   32           27.81--36.20   47.1±1.6   34.2±2.1   \<0.001
    T2                      3,996   27           25.24--28.76   42.0±0.9   31.0±1.1   
    T3                      3,419   23           21.53--24.47   38.5±1.0   29.3±1.1   
    T4                      2,005   14           12.90--15.10   26.3±1.2   17.9±1.3   
  AJCC (7th) N stage (45)                                                             
    N0                      3,362   29           26.56--31.44   45.3±1.0   34.2±1.2   \<0.001
    N1                      2,293   35           31.84--38.16   48.6±1.3   36.9±1.5   
    N2                      4,323   18           17.03--18.97   31.1±0.8   21.9±0.9   
    N3                      766     13           11.91--14.08   22.0±1.8   13.8±2.0   
  Primary site                                                                        
    Main bronchus           302     12           9.78--14.21    33.9±0.9   25.4±1.0   \<0.001
    Upper lobe              6,650   24           22.86--25.13   39.4±0.7   30.2±0.8   
    Middle lobe             460     28           23.24--32.76   43.6±2.8   31.9±3.4   
    Lower lobe              3,332   23           21.49--24.51   37.9±1.0   26.6±1.2   
  Laterality                                                                          
    Left                    4,448   23           21.64--24.37   38.9±0.9   29.4±1.0   0.346
    Right                   6,296   23           21.85--24.15   38.5±0.7   27.9±0.8   
  Surgery                                                                             
    None                    5,757   13           12.49--13.51   20.2±0.7   12.2±0.7   \<0.001
    Wedge resection         351     30           24.78--35.22   45.9±3.2   35.6±3.7   
    Segmental resection     114     41           28.39--53.61   52.5±5.9   37.6±7.2   
    Lobectomy               4,522   56           51.17--60.83   60.4±0.9   47.9±1.1   
  Lymph node dissection                                                               
    None                    5,652   13           12.49--13.51   20.2±0.7   12.2±0.7   \<0.001
    1--3                    651     40           33.07--46.93   45.9±3.2   35.6±3.7   
    ≥4                      4,441   53           48.87--23.87   60.4±0.9   47.9±1.1   
  Radiation                                                                           
    No                      5,152   19           18.17--19.83   33.9±0.9   25.4±1.0   \<0.001
    Yes                     5,592   29           27.12--30.88   45.1±0.8   35.5±0.9   
  Chemotherapy                                                                        
    No                      4,185   18           16.81--19.19   33.9±0.9   25.4±1.0   \<0.001
    Yes                     6,559   27           25.73--28.27   41.6±0.7   30.5±0.9   

OS, overall survival; ADC, adenocarcinoma; SCC, squamous cell carcinoma; LCC, large cell carcinoma; ASC, adenosquamous carcinoma; AJCC (7th), American Joint Committee on Cancer.

###### 

Clinical characteristics of the validation set.

                                    OS, months   OS, %                                
  ------------------------- ------- ------------ -------------- ---------- ---------- ---------
  Age                                                                                 
    ≤60                     1,041   30           24.54--34.54   45.7±1.8   34.6±2.1   \<0.001
    \>60                    3,559   21           19.68--22.31   34.6±1.0   23.7±1.1   
  Sex                                                                                 
    Male                    2,507   20           18.77--21.22   31.7±1.1   22.3±1.2   \<0.001
    Female                  2,093   28           25.31--30.69   43.9±1.3   31.3±1.6   
  Marital status                                                                      
    Married                 2,519   26           24.01--27.98   41.8±1.2   30.0±1.3   \<0.001
    Unmarried               2,081   20           18.44--21.55   31.5±1.2   21.5±1.4   
  Race                                                                                
    Caucasian               3,713   22           20.68--23.32   36.8±0.9   26.1±1.1   0.035
    African-American        547     22           19.31--24.68   35.2±2.5   26.3±2.7   
    Other                   340     31           25.94--36.05   44.2±3.4   25.4±3.9   
  Histology                                                                           
    ADC                     2,420   31           28.66--33.33   41.8±1.2   30.0±1.3   \<0.001
    SCC                     2,026   16           14.69--17.30   28.1±1.2   19.1±1.3   
    LCC                     103     30           18.56--41.43   43.9±5.8   33.4±6.1   
    ASC                     31      15           7.23--22.77    31.5±1.2   21.5±1.4   
  Grade                                                                               
    I                       370     41           30.81--51.18   52.0±3.1   40.1±3.9   \<0.001
    II                      1,837   26           23.79--28.20   40.7±1.4   27.4±1.6   
    III                     2,334   19           17.62--20.37   32.2±1.2   23.0±1.2   
    IV                      59      20           9.21--30.78    37.2±7.1   30.1±7.4   
  AJCC (7th) T stage (45)                                                             
    T1                      601     37           28.94--45.05   50.9±2.4   35.1±3.0   \<0.001
    T2                      1,718   25           22.64--27.35   39.6±1.4   27.3±1.6   
    T3                      1,444   23           21.08--24.91   36.5±1.5   26.0±1.7   
    T4                      837     13           11.45--14.54   23.4±1.8   16.0±1.9   
  AJCC (7th) N stage (45)                                                             
    N0                      1,433   30           26.09--33.90   45.6±1.6   35.4±1.9   \<0.001
    N1                      990     34           29.35--38.46   48.7±1.9   32.3±2.3   
    N2                      1,848   18           16.68--19.32   27.9±1.2   18.6±1.3   
    N3                      329     13           10.62--15.37   19.7±2.8   4.5±3.5    
  Primary site                                                                        
    Main bronchus           118     14           9.43--18.57    18.1±4.4   12.1±5.7   \<0.001
    Upper lobe              2,869   22           20.46--23.53   37.0±1.1   25.4±1.2   
    Middle lobe             181     22           17.03--26.96   36.2±4.3   32.2±4.7   
    Lower lobe              1,432   25           22.55--27.48   39.2±1.6   28.6±1.8   
  Laterality                                                                          
    Left                    1,913   23           20.98--25.01   37.7±1.3   26.2±1.5   0.932
    Right                   2,687   23           21.48--24.51   36.8±1.1   26.4±1.2   
  Surgery                                                                             
    None                    2,433   13           12.23--13.77   17.9±1.0   9.4±1.0    \<0.001
    Wedge resection         163     35           26.19--43.80   47.8±5.0   30.7±6.5   
    Segmental resection     45      31           24.01--37.98   46.9±9.1   37.5±9.4   
    Lobectomy               1,959   50           44.69--55.03   60.0±1.3   45.3±1.6   
  Lymph node dissection                                                               
    None                    2,398   13           12.20--13.79   18.3±1.0   10.1±1.0   \<0.001
    1--3                    306     35           29.49--40.51   46.5±3.4   29.2±4.2   
    ≥4                      1,896   50           44.13--55.87   59.5±1.4   45.4±1.7   
  Radiation                                                                           
    No                      2,176   19           17.75--20.25   28.6±1.2   19.3±1.2   \<0.001
    Yes                     2,424   30           27.34--32.65   44.9±1.2   32.7±1.4   
  Chemotherapy                                                                        
    No                      1,812   18           16.04--19.96   33.9±1.3   24.9±1.5   \<0.001
    Yes                     2,788   25           23.32--26.67   39.3±1.1   27.3±1.3   

OS, overall survival; ADC, adenocarcinoma; SCC, squamous cell carcinoma; LCC, large cell carcinoma; ASC, adenosquamous carcinoma; AJCC (7th), American Joint Committee on Cancer.

###### 

Results of the univariate and multivariate Cox regression analysis.

                            Univariate analysis                  Multivariate analysis                              
  ------------------------- --------------------- -------------- ----------------------- ----------- -------------- ---------
  Age                                                                                                               
    ≤60                     Reference                                                    Reference                  
    \>60                    1.479                 1.383--1.581   \<0.001                 1.293       1.208--1.205   \<0.001
  Sex                                                                                                               
    Male                    Reference                                                    Reference                  
    Female                  0.762                 0.723--0.804   \<0.001                 0.770       0.728--0.813   \<0.001
  Marital status                                                                                                    
    Married                 Reference                                                    Reference                  
    Unmarried               1.167                 1.108--1.229   \<0.001                 1.103       1.043--1.165   \<0.001
  Race                                                                                                              
    Caucasian               Reference                                                    Reference                  
    African-American        0.987                 0.911--1.069   0.745                   0.893       0.822--0.968   0.007
    Other                   0.804                 0.725--0.890   \<0.001                 0.825       0.744--0.914   \<0.001
  Histology                                                                                                         
    ADC                     Reference                                                    Reference                  
    SCC                     1.651                 1.566--1.741   \<0.001                 1.210       1.143--1.281   \<0.001
    LCC                     1.261                 1.068--1.488   0.006                   1.367       1.157--1.614   \<0.001
    ASC                     1.369                 1.090--1.720   0.007                   1.031       0.796--1.336   0.816
  Grade                                                                                                             
    I                       Reference                                                    Reference                  
    II                      1.159                 1.036--1.297   0.010                   1.140       1.016--1.280   0.025
    III                     1.423                 1.274--1.589   \<0.001                 1.290       1.152--1.445   \<0.001
    IV                      1.490                 1.184--1.874   0.001                   1.387       1.073--1.792   0.013
  AJCC (7th) T stage (45)                                                                                           
    T1                      Reference                                                    Reference                  
    T2                      1.170                 1.069--1.281   0.001                   1.094       0.997--1.199   0.056
    T3                      1.333                 1.216--1.461   \<0.001                 1.275       1.158--1.405   \<0.001
    T4                      1.900                 1.725--2.092   \<0.001                 1.387       1.247--1.530   \<0.001
  AJCC (7th) N stage (45)                                                                                           
    N0                      Reference                                                    Reference                  
    N1                      0.864                 0.799--0.935   \<0.001                 1.248       1.147--1.358   \<0.001
    N2                      1.442                 1.354--1.535   \<0.001                 1.478       1.379--1.584   \<0.001
    N3                      1.915                 1.733--2.116   \<0.001                 1.501       1.349--1.668   \<0.001
  Primary site                                                                                                      
    Main bronchus           Reference                                                    Reference                  
    Upper lobe              0.559                 0.488--0.641   \<0.001                 0.887       0.773--1.019   0.092
    Middle lobe             0.499                 0.414--0.602   \<0.001                 0.893       0.739--1.079   0.244
    Lower lobe              0.582                 0.505--0.669   \<0.001                 1.022       0.885--1.180   0.762
  Laterality                                                                                                        
    Left                    Reference                                                    NS                         
    Right                   1.025                 0.973--1.081   0.353                   NS                         
  Surgery                                                                                                           
    None                    Reference                                                    Reference                  
    Wedge resection         0.446                 0.381--0.522   \<0.001                 0.488       0.409--0.582   \<0.001
    Segmental resection     0.392                 0.292--0.526   \<0.001                 0.453       0.330--0.622   \<0.001
    Lobectomy               0.300                 0.283--0.318   \<0.001                 0.389       0.334--0.452   \<0.001
  Lymph node dissection                                                                                             
    None                    Reference                                                    Reference                  
    1--3                    0.395                 0.350--0.447   \<0.001                 0.815       0.697--0.953   0.010
    ≥4                      0.312                 0.294--0.331   \<0.001                 0.742       0.641--0.857   \<0.001
  Radiation                                                                                                         
    No                      Reference                                                    Reference                  
    Yes                     0.751                 0.712--0.791   \<0.001                 0.756       0.710--0.805   \<0.001
  Chemotherapy                                                                                                      
    No                      Reference                                                    Reference                  
    Yes                     0.706                 0.670--0.744   \<0.001                 0.632       0.596--0.670   \<0.001

ADC, adenocarcinoma; SCC, squamous cell carcinoma; LCC, large cell carcinoma; ASC, adenosquamous carcinoma; AJCC, American Joint Committee on Cancer; NS, not significant.

###### 

Scores of every subgroup within each variable.

  Variable                  Points   Variable                       Points
  ------------------------- -------- ------------------------------ --------
  Age                                Sex                            
    ≤60                     0        Male                           27
    \>60                    27       Female                         0
  Chemotherapy                       Radiation                      
    No                      49       No                             30
    Yes                     0        Yes                            0
  AJCC (7th) T stage (45)            AJCC (7th) Nstage(45)          
    T1                      0        N0                             0
    T2                      10       N1                             23
    T3                      22       N2                             41
    T4                      33       N3                             43
  Race                               Extentoflymph nodedissection   
    Caucasian               20       None                           31
    African-American        7        1--3                           10
    Other                   0        ≥4                             0
  Histology                          Grade                          
    AC                      0        I                              0
    SC                      21       II                             13
    ASC                     33       III                            25
    LCC                     3        IV                             33
  Surgery                            Marital status                 
    None                    100      Married                        0
    Wedgeresection          23       Unmarried                      10
    Segmentalresection      15                                      
    Lobectomy               0                                       

ADC, adenocarcinoma; SCC, squamouscellcarcinoma; LCC, largecellcarcinoma; ASC, adenosquamous carcinoma; AJCC, American Joint Committeeon Cancer.

[^1]: Contributed equally
